月曜日 09:00 - 18:00 火曜日 09:00 - 18:00 水曜日 09:00 - 18:00 木曜日 09:00 - 18:00 金曜日 09:00 - 18:00

Igenomix APAC

ホーム
日本
Minato, Tokyo
Igenomix APAC

We work to make a world in which infertility is no longer an impossible barrier.

Vitrolife & Igenomix APAC, Part of Vitrolife Group
🧬 Advanced Reproductive Genetic Services
🤰🏻 We work to enable people to fulfill the dream of having a healthy baby. Together with clinics and fertility doctors worldwide, we investigate human reproduction to change the lives of couples who are trying to conceive. We are a reference company in reproductive genetics, and we are willing to change the way IVF is performed with just one goal on mind: a healthy baby at home.

06/08/2025

💡 Smarter EMMA&ALICE reporting
Our latest update brings simplified and easier-to-interpret results — giving you greater clarity and confidence when evaluating the endometrial microbiome.

🔸 What’s new in the reporting format?
🔸 Swipe for key benefits or click to learn more

👉 Read more about EMMA&ALICE: https://www.igenomix.eu/genetic-solutions/emma-endometrial-microbiome-metagenomic-analysis/

10/07/2025

🌐Join us for our upcoming APAC Webinar — Highlights from 2025! Get the latest scientific and clinical updates from Paris🗼

Our regional team of experts will share key takeaways from the conference, with a focus on current trends and the future direction of assisted reproductive technologies (ART).

ESHRE Highlights: Scientific and clinical updates from Paris
📆 Thursday 24th July 2025
⌚ 18:00 – 19:00 (JST) / 19:00 – 20:00 (AEST)

Register https://us06web.zoom.us/webinar/register/WN_vEEXpXiaSUqnzCZiB54VPw #/registration

02/07/2025

Welcome to
👋 We are ready to meet you in our Booth C006. Join us and explore our full range of innovative portfolio of products & services.

Listen to inspiring presentations in the Academy Studio and experience hands-on live demonstration of our Sense needle, eWitness and the new Ultra-fast warming media.

Follow the program here ➤ https://lnkd.in/dPxR-f9C

27/06/2025

🌍 Celebrating World Microbiome Day!

At Igenomix, Part of Vitrolife Group, we recognize the essential role of the uterine microbiome in reproductive health. Our EMMA-ALICE tests helps identify imbalances and infections in the endometrial environment, empowering clinicians to personalize fertility treatments and improve outcomes.

Today, we’re proud to highlight how Vitrolife Group combines Science and Innovation to support healthy beginnings for families everywhere.

25/06/2025

💡Check out our first day of scientific presentations taking place at European Society of Human Reproduction and Embryology (ESHRE) 2025 next week in Paris!

📣 Can't join in person this year? All presentations will be live-streamed from our Vitrolife, Part of Vitrolife Group or Igenomix, Part of Vitrolife Group LinkedIn pages.

👉 Find more information and the full program here: https://lnkd.in/eN9AkFnz

21/06/2025

🎉 is just a couple weeks away, and we are excited to come together to learn and share the latest in reproductive health! Have you had the chance to explore our exciting lineup of Academy Studio presentations?

💡 Don’t miss this opportunity to connect with leading experts, exchange ideas and gain valuable knowledge that can help transform your daily practice.

European Society of Human Reproduction and Embryology (ESHRE)

21/06/2025

💡Vitrolife Group is driven by excellence in science and innovation. This year, we are happy to present seven oral presentations and posters accepted by ESHRE.

Explore the Vitrolife Group Scientific Program for ESHRE 2025 and discover what’s shaping the future of reproductive health:
https://lnkd.in/dPxR-f9C

13/06/2025

Published Data Shows 🙌 Nearly Doubled Live Birth Rates 🙌 for RIF Patients when Utilizing the ERA Test

📣 A new multicenter study of 270 patients with one or more failed embryo transfers shows that ERA-guided personalized embryo transfer (pET) significantly improves clinical outcomes when using euploid embryos.

Key Findings:
🔹 Pregnancy Rate: 65.0% (ERA) vs. 37.1% (standard ET)
🔹 Ongoing Pregnancy Rate: 49.0% vs. 27.1%
🔹 Live Birth Rate: 48.2% vs. 26.1%

📈 These findings support ERA-guided pET as a promising approach for patients with recurrent implantation failure — offering a new era in reproductive medicine.

➡️ Visit the new ERA Insight Hub to access the full publication and more:
https://lnkd.in/d7ennM5a

10/06/2025

Only a few weeks remain until ESHRE 2025, and we look forward to connecting with you in Paris! Visit us at our booth during the congress for live demonstrations, engaging webinars and to explore our latest innovations💡

Read more about what we have planned here:
https://ow.ly/u6sH50W2rSy

顯示翻譯

06/06/2025

🌟Research update!

We recently published a review article in the journal Genes, where we performed a comprehensive review of non-invasive preimplantation genetic testing for aneuploidy (niPGT-A).

What was our objective?

Our aim with this article was to provide a thorough and balanced review of the existing literature related to niPGT-A, including aspects such as the origin of embryonic cell-free DNA, embryo culture protocol modifications, clinical outcomes, and common concerns & barriers related to implementation of a niPGT-A program.

Key messages:

🧬Protocol modifications: Specific measures in the IVF laboratory are required to maximise the amount of cfDNA present in the final media sample, as well as to reduce the risk of maternal or exogenous contamination. These protocol changes do not have a deleterious effect on embryo viability, developmental potential, or reproductive outcomes.

🧬Clinical outcomes: Non-invasive PGT-A using SBM, in combination with morphology evaluation could significantly improve clinical outcomes in assisted reproduction cycles. A prioritisation-based approach could utilise the top-ranked blastocysts for the first transfer, while the remaining embryos could be stored for future cycles.

🧬Important considerations: Clinic-based guidelines for reporting, results interpretation, and treatment management are key factors in successfully implementing niPGT-A. Aspects such as maternal and exogenous contamination and embryonic mosaicism must be considered and carefully discussed with patients.

Want to learn more about non-invasive PGT-A? Check out the full paper here: 👉https://www.mdpi.com/3294132, or scan the QR code below.

02/06/2025

We’re excited to share that Vitrolife Group will be attending the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) taking place in Paris. We look forward to welcoming you at our booth C006 during the congress.

Further details about our activities at ESHRE 2025 will be shared, stay tuned!